| Literature DB >> 22479463 |
Sabrina Klem1, Mario Klingler, Hans Demmelmair, Berthold Koletzko.
Abstract
BACKGROUND: Red blood cell (RBC) n-3 fatty acid status is related to various health outcomes. Accepted biological markers for the fatty acid status determination are RBC phospholipids, phosphatidylcholine, and phosphatidyletholamine. The analysis of these lipid fractions is demanding and time consuming and total phospholipid n-3 fatty acid levels might be affected by changes of sphingomyelin contents in the RBC membrane during n-3 supplementation. AIM: We developed a method for the specific analysis of RBC glycerophospholipids. The application of the new method in a DHA supplementation trial and the comparison to established markers will determine the relevance of RBC GPL as a valid fatty acid status marker in humans.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22479463 PMCID: PMC3316509 DOI: 10.1371/journal.pone.0033874
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Intra- and inter-assay reproducibility of the GPL fatty acid analysis.
| Intra-assay (n = 8) | Inter-assay (n = 26) | |||||
| Mean | SD | CV [%] | Mean | SD | CV [%] | |
|
| ||||||
| C14:0 | 0.35 | 0.01 | 3.7 | 0.32 | 0.04 | 12.6 |
| C16:0 | 22.99 | 1.01 | 4.4 | 23.31 | 0.80 | 3.4 |
| C17:0 | 0.34 | 0.02 | 4.6 | 0.32 | 0.04 | 11.3 |
| C18:0 | 18.34 | 0.27 | 1.5 | 17.92 | 0.40 | 2.3 |
|
| ||||||
| C16:1n-7 | 0.29 | 0.02 | 7.6 | 0.35 | 0.03 | 8.6 |
| C18:1n-7 | 1.45 | 0.03 | 2.0 | 1.42 | 0.15 | 10.9 |
| C18:1n-9 | 14.07 | 0.22 | 1.5 | 13.38 | 0.22 | 1.6 |
| C20:1n-9 | 0.29 | 0.00 | 3.3 | 0.27 | 0.01 | 4.9 |
|
| ||||||
| C20:3n-9 | 0.11 | 0.00 | 4.2 | 0.11 | 0.01 | 9.5 |
|
| ||||||
| C18:2n-6 | 11.84 | 0.50 | 4.3 | 12.34 | 0.16 | 1.3 |
| C18:3n-6 | 0.06 | 0.00 | 3.7 | 0.08 | 0.01 | 10.1 |
| C20:2n-6 | 0.22 | 0.01 | 6.4 | 0.25 | 0.01 | 5.3 |
| C20:3n-6 | 2.37 | 0.02 | 1.0 | 2.21 | 0.04 | 1.7 |
| C20:4n-6 | 15.39 | 0.84 | 5.5 | 15.57 | 0.55 | 3.5 |
| C22:4n-6 | 2.37 | 0.25 | 10.5 | 3.20 | 0.20 | 6.3 |
| C22:5n-6 | 0.67 | 0.02 | 3.0 | 0.64 | 0.03 | 5.0 |
|
| ||||||
| C18:3n-3 | 0.15 | 0.01 | 4.6 | 0.10 | 0.01 | 8.7 |
| C20:5n-3 | 0.75 | 0.04 | 5.5 | 0.69 | 0.05 | 6.6 |
| C22:5n-3 | 2.35 | 0.22 | 9.3 | 2.31 | 0.14 | 6.2 |
| C22:6n-3 | 5.68 | 0.17 | 2.9 | 5.16 | 0.26 | 5.0 |
Mean and SD are expressed as %wt/wt.
Figure 1Recovery of total RBC fatty acids using different extraction procedures (P<0.05).
Changes in fatty acids (%wt/wt) during storage of RBC samples (n = 13) in methanol over a period of 8 months at −80°C.
| Analysis without storage | Analysis after 8 months storage | Difference | ||||
| Mean | SD | Mean | SD | [%] |
| |
| C14:0 | 0.28 | 0.07 | 0.29 | 0.08 | 4.09 |
|
| C16:0 | 22.62 | 1.21 | 22.81 | 1.00 | 0.85 |
|
| C17:0 | 0.33 | 0.04 | 0.42 | 0.08 | 29.50 |
|
| C18:0 | 17.75 | 0.55 | 17.26 | 0.58 | −2.75 |
|
| C16:1n-7 | 0.35 | 0.13 | 0.37 | 0.14 | 6.90 |
|
| C18:1n-7 | 1.35 | 0.11 | 1.39 | 0.12 | 3.32 |
|
| C18:1n-9 | 15.04 | 0.89 | 14.73 | 0.74 | −2.03 |
|
| C20:1n-9 | 0.31 | 0.07 | 0.29 | 0.04 | −7.59 |
|
| C20:3n-9 | 0.11 | 0.03 | 0.10 | 0.02 | −3.45 |
|
| C18:2n-6 | 11.79 | 1.29 | 11.57 | 1.10 | −1.90 |
|
| C18:3n-6 | 0.06 | 0.03 | 0.07 | 0.03 | 31.97 |
|
| C20:2n-6 | 0.28 | 0.04 | 0.26 | 0.03 | −6.41 |
|
| C20:3n-6 | 1.91 | 0.43 | 1.82 | 0.39 | −4.42 |
|
| C20:4n-6 | 16.04 | 1.24 | 16.63 | 0.86 | 3.69 |
|
| C22:4n-6 | 2.76 | 0.44 | 3.19 | 0.52 | 15.79 |
|
| C22:5n-6 | 0.78 | 0.15 | 0.70 | 0.15 | −9.74 |
|
| C18:3n-3 | 0.14 | 0.03 | 0.14 | 0.03 | −1.15 |
|
| C20:5n-3 | 0.58 | 0.21 | 0.60 | 0.20 | 3.10 |
|
| C22:5n-3 | 2.04 | 0.31 | 2.22 | 0.35 | 8.44 |
|
| C22:6n-3 | 5.61 | 1.16 | 5.26 | 0.93 | −6.30 |
|
Differences in fatty acid contents caused through sample storage were related to fatty acid contents of samples without storage. Mean and SD are expressed as %wt/wt. n.s.: not significant.
Effects of DHA supplementation on fatty acid composition (%wt/wt) of individual RBC PL fractions.
| PC | PE | GPL | PL | |||||||||||||||||
| study start | study end | study start | study end | study start | study end | study start | study end | |||||||||||||
| mean | SD | mean | SD | % diff | mean | SD | mean | SD | % diff | mean | SD | mean | SD | % diff | mean | SD | mean | SD | % diff | |
|
| 36.2 | 1.3 | 36.0 | 1.4 | −0.5 | 17.7 | 1.9 | 17.3 | 1.5 | −2.6 | 22.4 | 1.1 | 22.8 | 0.8* | 1.9 | 25.6 | 1.1 | 27.6 | 1.5* | 8.0 |
|
| 10.6 | 1.1 | 10.4 | 1.1 | −1.6 | 8.4 | 1.1 | 8.1 | 0.5 | −3.6 | 17.3 | 0.5 | 16.8 | 0.6** | −3.0 | 18.5 | 0.7 | 19.1 | 1.4 | 4.7 |
|
| 0.6 | 0.2 | 0.6 | 0.2 | 15.6 | 0.3 | 0.1 | 0.2 | 0.1 | −6.7 | 0.4 | 0.1 | 0.4 | 0.1 | −5.7 | 0.3 | 0.1 | 0.4 | 0.1 | 46.4 |
|
| 2.0 | 0.1 | 2.1 | 0.1 | 1.0 | 1.4 | 0.3 | 1.3 | 0.1 | −9.0 | 1.4 | 0.1 | 1.3 | 0.1* | −5.3 | 1.2 | 0.2 | 1.1 | 0.1 | −3.9 |
|
| 17.2 | 1.1 | 17.0 | 1.1 | −1.4 | 17.3 | 0.9 | 17.0 | 1.2 | −8.8 | 14.6 | 0.8 | 14.5 | 0.7 | −0.7 | 13.3 | 0.8 | 13.1 | 0.7* | −1.7 |
|
| 0.1 | 0.0 | 0.1 | 0.0 | −3.3 | 0.1 | 0.0 | 0.1 | 0.0 | 8.6 | 0.1 | 0.0 | 0.1 | 0.0 | −5.8 | 0.1 | 0.0 | 0.1 | 0.0 | 31.1 |
|
| 19.5 | 1.6 | 19.7 | 1.6 | 1.2 | 5.6 | 0.9 | 5.4 | 0.9 | −4.0 | 11.6 | 1.2 | 11.3 | 1.0 | −2.1 | 10.2 | 1.0 | 9.9 | 0.8 | −2.1 |
|
| 0.1 | 0.0 | 0.1 | 0.0 | −6.4 | 0.1 | 0.0 | 0.1 | 0.0 | 0.4 | 0.1 | 0.0 | 0.1 | 0.0 | −5.0 | 0.1 | 0.0 | 0.1 | 0.0 | 20.5 |
|
| 2.1 | 0.6 | 2.1 | 0.5 | −2.9 | 1.3 | 0.3 | 1.2 | 0.2 | −3.4 | 1.9 | 0.4 | 1.7 | 0.4*** | −7.7 | 1.6 | 0.5 | 1.4 | 0.4*** | −14.6 |
|
| 6.8 | 1.0 | 6.4 | 0.9 | −5.8 | 25.4 | 1.9 | 25.5 | 1.4 | −0.6 | 16.8 | 0.9 | 16.1 | 0.7* | −3.9 | 16.3 | 1.1 | 14.7 | 0.9*** | −9.5 |
|
| 0.4 | 0.1 | 0.3 | 0.0 | −6.9 | 8.2 | 1.1 | 7.8 | 1.0* | −6.0 | 3.1 | 0.6 | 3.2 | 0.5 | 2.2 | 3.7 | 0.4 | 3.1 | 0.4*** | −16.2 |
|
| 0.2 | 0.1 | 0.1 | 0.0 | −3.0 | 1.0 | 0.2 | 0.9 | 0.2** | −13.3 | 0.7 | 0.2 | 0.7 | 0.1*** | −11.0 | 0.6 | 0.2 | 0.4 | 0.2*** | −36.7 |
|
| 0.2 | 0.1 | 0.2 | 0.1 | 19.3 | 0.1 | 0.0 | 0.1 | 0.0 | 15.1 | 0.1 | 0.0 | 0.1 | 0.0 | 2.0 | 0.1 | 0.0 | 0.1 | 0.0 | −9.7 |
|
| 0.5 | 0.4 | 0.5 | 0.1 | 27.5 | 1.0 | 0.3 | 1.0 | 0.3 | 4.3 | 0.6 | 0.3 | 0.6 | 0.1 | 9.3 | 0.6 | 0.2 | 0.6 | 0.2 | 9.5 |
|
| 0.5 | 0.1 | 0.4 | 0.1* | −12.5 | 4.5 | 0.6 | 4.2 | 0.6*** | −7.9 | 2.3 | 0.4 | 2.1 | 0.3 | −4.4 | 2.3 | 0.3 | 1.9 | 0.4** | −17.4 |
|
| 1.4 | 0.2 | 2.6 | 0.5*** | 92.3 | 6.2 | 0.9 | 8.3 | 0.9*** | 33.2 | 4.6 | 0.8 | 5.8 | 0.6*** | 27.3 | 4.3 | 0.8 | 4.9 | 0.9** | 13.3 |
Differences between study start and end were based on baseline values. Paired t-test: *p<0.05, **p<0.01, *p<0.001.
Correlations between RBC GPL fatty acids and other RBC PL fractions before and after n-3 supplementation.
| Correlation of individual GPL fatty acids | ||||||
|
|
|
| ||||
| R |
| R |
| R |
| |
| C16:0 | 0.525 | n.s. | 0.081 | n.s. | 0.343 | n.s. |
| C18:0 | 0.529 | n.s. | 0.291 | n.s. | 0.162 | n.s. |
| C16:1n-7 | 0.801 | 0.001 | 0.893 | <0.001 | 0.874 | <0.001 |
| C18:1n-7 | 0.509 | n.s. | 0.725 | 0.005 | 0.409 | n.s. |
| C18:1n-9 | 0.919 | <0.001 | 0.441 | n.s. | 0.898 | <0.001 |
| C20:3n-9 | 0.352 | n.s. | 0.142 | n.s. | 0.743 | 0.006 |
| C18:2n-6 | 0.797 | 0.001 | 0.446 | n.s. | 0.970 | <0.001 |
| C18:3n-6 | 0.436 | n.s. | 0.104 | n.s. | 0.427 | n.s. |
| C20:3n-6 | 0.766 | 0.002 | 0.905 | <0.001 | 0.967 | <0.001 |
| C20:4n-6 | 0.625 | 0.022 | 0.497 | n.s. | 0.473 | n.s. |
| C22:5n-6 | 0.746 | 0.003 | 0.909 | <0.001 | 0.820 | 0.001 |
| C18:3n-3 | 0.930 | <0.001 | 0.723 | 0.005 | 0.566 | n.s. |
| C20:5n-3 | 0.899 | <0.001 | 0.779 | 0.002 | 0.966 | <0.001 |
| C22:5n-3 | 0.739 | 0.004 | 0.704 | 0.007 | 0.594 | 0.042 |
| C22:6n-3 | 0.555 | 0.049 | 0.818 | <0.001 | 0.940 | <0.001 |
n.s. not significant.
Figure 2Correlation of RBC total PL and RBC GPL omega-3 index (n = 13).